|
Stakeholder Driven Device Innovation in Pulmonary and Nasal Drug Delivery Troels Keldmann Direct-haler A/S |
Biography Troels Keldmann is co-founder of Direct-Haler and co-inventor of the key technology and therapeutic patents underpinning the companys core business. He holds a B.Sc. in Medico Engineering, and a M.Sc. in Technology Management from Technical University of Denmark. Hereafter, he worked as consultant for Institute for Product Development, an engineering design & management consultancy. He returned to Technical University of Denmark to complete a Ph.D. in Management of Product Development, and has since 1997 been Managing Director of Direct-Haler A/S. In 2007 he initiated the development of a software based system for management of research and development in the hospital sector. These activities are based in the company Keldmann Innovation A/S. Company Profile
|
Abstract Driven by the need for patient-friendliness and enhanced performance, pulmonary inhalation devices and nasal delivery devices are becoming increasingly complex. Designs typically evolve from known multi-dose device concepts, adding new components whenever additional functionality is needed. However, it is easy to confuse sophistication with increased complexity. New development approaches seek to create value not only for the patients (end-users) but also for other device “users”; the General Practitioner, physicians and nurses. The broad scope also includes internal stakeholders: Clinical development who apply the device in clinical trials, manufacturing and supply who integrate the device with the manufacture of the complete pharmaceutical product, and sales representatives who need a “new story” to get access to the GPs.
|
